Enhancement of interleukin-2-induced lymphokine-activated killer activity by interleukin 7 against autologous human renal cell carcinoma

Oncology

Volumn 55, Issue 6, 1998, Pages 588-593

  Kondo, Masahiko ^a   Nonomura, Norio ^a   Miki, Tsuneharu ^a   Kojima, Yasuyuki ^a   Yokoyama, Masayoshi ^b   Nakano, Etsuji ^a   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b EHIME UNIVERSITY   (Japan)

Author keywords

Interleukin 2; Interleukin 7; Lymphokine activated killer cell; Renal cancer

Indexed keywords

INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 7;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; KIDNEY CARCINOMA; LYMPHOKINE ACTIVATED KILLER CELL; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

AGED; ANTIGENS, CD; CARCINOMA, RENAL CELL; DNA, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; INTERLEUKIN-7; KIDNEY NEOPLASMS; KILLER CELLS, LYMPHOKINE-ACTIVATED; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED;

EID: 0031725149     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000011917     Document Type: Article

References (28)

1. Umeda T, Niijima T: Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials. Cancer 1986;58: 1231-1235.
2. Nakano E, Tada Y, Ichikawa Y, Fujioka H, Matsuda M, Takaha M, Sonoda T: Lysis of autologous tumor cells by peripheral blood lymphocytes treated with interleukin 2 in patients with renal cell carcinoma. J Urol 1987; 137:641-648.
3. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982;155:1823-1841.
4. Grimm EA, Ramsey KM, Mazumder A, Wilson DJ, Djeu JY, Rosenberg SA: Lymphokine-acivated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes and natural killer cells. J Exp Med 1983;157:884-897.
5. Rosenberg SA: Lymphokine-activated killer cells. J Natl Cancer Inst 1985;75:595-603.
6. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Lineha WM, Robertson CN, Lee RE, Rubin JT, Aeipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-897.
7. Fisher RI, Coltman CA Jr, Doroshow JH, Rayner AA, Hawkins MJ, Mier JW, Wiernik P, McMannis JD, Weis GR, Margolin KA, Gemlo BT, Hoth DF, Parkinson DR, Paietta E: Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells: A phase II clinical trial. Ann Intern Med 1988;108:518-523.
8. Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C, Rugarli C, Masse HVD, Thatcher N, Symann M, Bartsch HH, Bergmann L, Bijman JT, Palmer PA, Franks CR: Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: A report of a European multicenter study. Eur J Cancer Clin Oncol 1989;25:s21-s28.
9. Nakano E: Lymphokine-activated killer (LAK) therapy for metastatic renal cell carcinoma. Acta Urol Jpn 1992;38:1305-1309.
10. Rosenberg SA: Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin 2. J Biol Response Modif 1984;3: 501-511.
11. Namen AE, Schmierer E, March CL, Overell RW, Park LS, Urdal DL. Mochizuki DY: B-cell precursor growth-promoting activity: Purification and characterization of a growth factor active on lymphocyte precursors. J Exp Med 1988;167:988-1002.
12. Namen AE, Lupton S, Hjerrild K, Wignall J, Mochizuki DY, Schmierer E, Moslay B, March CL, Urdal DL, Cosmos D, Goodwin RG: Stimulation of B-cell progenitors by cloned murine interleukin 7. Nature 1988;333:571-573.
13. Lynch DH, Miller RE: Induction of murine lymphokine-activated killer cells by recombinant IL-7. J Immunol 1990;145:1983-1990.
14. Robson CJ, Churchill BM, Anderson W: The results of radical nephrectomy for renal cell carcinoma. J Urol 1969;101:297-301.
15. The Japanese Urological Association, the Japanese Society of Pathology, Japan Radiological Society: General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma, ed 2. Tokyo, Kanehara, 1992, pp 44-105.
16. Böyume A: Isolation of leukocytes from human blood. Further observations: Methylcellulose, dextran, and ficoll as erythrocyte aggregating agents. Scand J Clin Lab Invest Suppl 1968;97: 21-31.
17. Mazumder A, Grimm EA, Zhang HZ, Rosenberg SA: Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro lectines. Cancer Res 1982;42:913-918.
18. Nishimura T, Terashima Y, Hattori T, Satoh M, Watanabe J, Kimura G, Yoshida K, Akimoto M: Study of cytotoxicity of recombinant interleukin-2 (rIL-2) expanded tumor infiltrating lymphocytes (TIL) in renal cell cancer. Jpn J Urol 1990;81:835-840.
19. Stötter H, Custer MC, Bolton ES, Guedez L, Lotze MT: IL-7 induces human lymphokine-activated killer cell activity and is regulated by IL-4. J Immunol 1991;146:150-155.
20. Alderson MR, Sassenfeld HM, Widmer MB: Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood. J Exp Med 1990;172:577-585.
21. Hickman JC, Crim JA, Mostowski HS, Siegel JP: Regulation of human cytotoxic T lymphocyte development by IL-7. J Immunol 1990; 145:2415-2420.
22. Bertagnolli M, Herrmann S: IL-7 supports the generation of cytotoxic T lymphocytes from thymocytes. Multiple lymphokines required for proliferation and cytotoxicity. J Immunol 1990;145:1706-1712.
23. Lynch DH, Namen AE, Miller RE: In vivo evaluation of the effects of interleukin 2, 4, and 7 on anti-tumor cytotoxic T lymphocytes. Eur J Immunol 1991;21:2977-2985.
24. Nakano E, Tada Y, Ichikawa Y, Fujioka H, Ishibashi M, Matsuda M, Takaha M, Sonoda T: Cytotoxic activity of peripheral blood lymphocytes grown with interleukin 2 against autologous cultured tumor cells in patients with renal cell carcinoma: Preliminary report. J Urol 1985;134:24-28.
25. Stötter H, Lotze MT: Human lymphokine-activated killer cell activity. Role of IL-2, IL-4 and IL-7. Arch Surg 1991;126:1525-1530.
26. Chazen GD, Pereira GMB, LeGros G, Gillis S, Shevach EM: Interleukin 7 is a T-cell growth factor. Proc Natl Acad Sci USA 1989;86:5923-5927.
27. Noguchi T, Nakamura Y, Russell SM, Ziegler SF, Tsang M, Cao X, Leonard WJ: Interleukin-2 receptor gamma chain: A functional component of the interleukin-7 receptor. Science 1993;262:1877-1880.
28. Morissey PJ, Goodwill RG, Norden RP, Anderson D, Grabstein KH, Cosman D, Sims J, Lupton S, Acres B, Reed SG, Mochizuki DY, Eisenman J, Conlon PJ, Namen AE: Recombinant interleukin 7, pre-B cell growth factor, has costimulatory activity on purified mature T cell. J Exp Med 1989;169:707-716.